Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis

Yasuto Araki 1,2,* and Toshihide Mimura 1,2

1 Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama 350-0495, Japan; toshim@saitama-med.ac.jp
2 Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama 350-0495, Japan
* Correspondence: arakiya@saitama-med.ac.jp; Tel.: +81-49-276-1462; Fax: +81-49-295-4849

Academic Editor: Masatoshi Maki
Received: 28 February 2017; Accepted: 19 April 2017; Published: 25 April 2017

Abstract: Matrix metalloproteinases (MMPs) are implicated in the degradation of extracellular matrix (ECM). Rheumatoid arthritis (RA) synovial fibroblasts (SFs) produce matrix-degrading enzymes, including MMPs, which facilitate cartilage destruction in the affected joints in RA. Epigenetic mechanisms contribute to change in the chromatin state, resulting in an alteration of gene transcription. Recently, MMP gene activation has been shown to be caused in RASFs by the dysregulation of epigenetic changes, such as histone modifications, DNA methylation, and microRNA (miRNA) signaling. In this paper, we review the role of MMPs in the pathogenesis of RA as well as the disordered epigenetic mechanisms regulating MMP gene activation in RASFs.

Keywords: matrix metalloproteinase; rheumatoid arthritis; epigenetics; gene transcription

1. Introduction

Proteases are enzymes that catalyze the hydrolysis of peptide bonds in polypeptide chains of target proteins. They stringently regulate numerous essential physiological processes, including autophagy, cellular protein degradation (through both lysosomes and the ubiquitin–proteasome system), the immune response, cell death, and signal transduction [1–4]. The dysregulation of protease activity can result in the development of a number of diseases, such as inflammatory diseases, cardiovascular diseases, cancer, and neurological diseases [5–8]. Therefore, several small molecules that specifically inhibit particular proteases have been developed as effective drugs [9].

To date, approximately 600 proteases have been identified in humans [10]. Proteases are divided into endopeptidases and exopeptidases. The endopeptidases, also called proteinases, hydrolyze internal peptide bonds of polypeptide chains. The exopeptidases include carboxypeptidases and aminopeptidases that cleave substrates at the carboxyl- and amino-termini of polypeptide chains, respectively. Based on the mechanisms of proteolysis, endopeptidases are grouped into five major classes, including aspartic, cysteine, threonine, serine, and metalloproteinases [11,12]. Aspartic, cysteine, and threonine proteinases are involved in intracellular pathways, whereas serine and metalloproteinases are associated with extracellular pathways. The metalloproteinases include matrix metalloproteinases (MMPs), which are involved in the pathogenesis of numerous diseases, such as rheumatoid arthritis (RA).

The mechanisms regulating MMP transcription have been clarified. Pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β, activate MMP genes through the binding of several different transcription factors (TFs), such as mitogen-activated protein kinase (MAPK),
nuclear factor-κB (NF-κB), and activator protein-1 (AP-1), to their promoters [13–15]. IL-6 is another pro-inflammatory cytokine that is associated with the pathogenesis of RA [16]. Recently, IL-6 was also reported to induce MMP gene activation through the binding of signal transducer and activator of transcription (STAT) 3 to MMP promoters in RA synovial fibroblasts (SFs) [17]. Epigenetic changes have been shown to affect chromatin structure without a change in DNA sequence itself. Therefore, both the chromatin state and the accessibility of TFs are thought to lead to aberrant gene transcription in RA. There is evidence that epigenetic mechanisms, such as histone modifications, DNA methylation and microRNA (miRNA) expression, contribute to MMP gene activation in several diseases, including RA.

2. The Structure and Function of Matrix Metalloproteinases

MMPs are a family of zinc-dependent metalloendopeptidases that play a critical role in the turnover of a variety of extracellular matrix (ECM) proteins [13,18]. The human MMP family currently consists of 23 members and is subdivided into five major subfamilies according to functional and structural properties: (1) the collagenases (MMP-1, MMP-8, and MMP-13); (2) the gelatinases (MMP-2 and MMP-9); (3) the stromelysins (MMP-3, MMP-10, and MMP-11); (4) a heterogenous subgroup, such as matrilysins (MMP-7 and MMP-26), enamelsin (MMP-20), macrophage metalloelastase (MMP-12), and others (MMP-19, MMP-21, MMP-23, MMP-27, and MMP-28); and (5) the membrane-type (MT)-MMPs—MMP-14 (MT1-MMP), MMP-15 (MT2-MMP), MMP-16 (MT3-MMP), MMP-17 (MT4-MMP), MMP-24 (MT5-MMP), and MMP-25 (MT6-MMP)—(Table 1) [19,20]. Substrates for the MMPs include most of the ECM components, such as collagen (types I, II, III, IV, V, VI, VII, VIII, IX, X, XI, and XIV), aggrecan, elastin, fibronectin, gelatin, and laminin. MMP-1, MMP-3, MMP-8, MMP-10, MMP-12, MMP-13, MMP-19, and MMP-20 contain several distinct subunits, such as a minimal domain, hinge region, and hemopexin-like C-terminal domain (Figure 1). The minimal domain is comprised of a signal peptide, a propeptide, and a catalytic domain. The signal peptide is cleaved by signal peptidases when the MMPs move to the endoplasmic reticulum. The propeptide contains a cysteine residue and a furin cleavage site (Arg–X–Lys–Arg motif) in MMP-11, MMP-21, MMP-23, MMP-28, and MT-MMPs. The interaction of the cysteine residue with the zinc ion of the catalytic domain renders the MMPs inactive. Pro-protein converting enzymes, such as furin, make the enzymes active by disrupting this interaction (this process is known as a cysteine switch). The hinge region links the catalytic domain to the hemopexin-like C-terminal domain. In the gelatinases (MMP-2 and MMP-9), three repeats of a fibronectin type II motif exist in the catalytic domain and enable them to bind and degrade gelatin. The hemopexin-like C-terminal domain, which is composed of four repeats that resemble hemopexin, determines substrate specificity. The hinge region and hemopexin-like C-terminal domain are absent from the matrilysins (MMP-7 and MMP-26). MMP-23 lacks a signal peptide and contains a type II transmembrane domain, a cysteine array, and an immunoglobulin-like domain. MT-MMPs are inserted in the plasma membrane by a type I transmembrane domain with a cytoplasmic domain (MMP-14, MMP-15, MMP-16, and MMP-24) or by a glycosylphosphatidylinositol (GPI) anchor (MMP-17 and MMP-25) [23].

| Enzyme | Pseudonyms | Collagen Substrates | Additional Substrates |
|--------|------------|---------------------|-----------------------|
| MMP-1  | Collagenase-1 | I, II, III, VII, VIII, X | Aggrecan, Gelatin |
| MMP-2  | Gelatinase A | I, II, III, IV, V, VII, X, XI | Aggrecan, Elastin, Fibronectin, Gelatin, Laminin |
| MMP-3  | Stromelysin-1 | II, II, III, IV, IX, X, XI | Aggrecan, Elastin, Fibronectin, Gelatin, Laminin |
| MMP-4  | Identified as MMP-3 | - | - |
| MMP-5  | Identified as MMP-2 | - | - |
| MMP-6  | Identified as MMP-3 | - | - |
| MMP-7  | Matrilysin | IV, X | Aggrecan, Elastin, Fibronectin, Gelatin, Laminin |
| MMP-8  | Collagenase-2 | I, II, III, V, VII, VIII, X | Aggrecan, Elastin, Fibronectin, Gelatin, Laminin |
| MMP-9  | Gelatinase B | IV, V, VII, X, XIV | Aggrecan, Elastin, Fibronectin, Gelatin |
| MMP-10 | Stromelysin-2 | III, IV, V | Aggrecan, Elastin, Fibronectin, Gelatin, Laminin |
| MMP-11 | Stromelysin-3 | Aggrecan, Fibronectin, Laminin | - |
| MMP-12 | Macrophage | IV | Elastin, Fibronectin, Gelatin, Laminin |
| MMP-13 | Collagenase-3 | I, II, III, IV | Aggrecan, Gelatin |
Table 1. Cont.

| Enzyme   | Pseudonyms     | Collagen Substrates       | Additional Substrates               |
|----------|----------------|---------------------------|-------------------------------------|
| MMP-14   | MT1-MMP        | I, II, III                | Aggrecan, Elastin, Fibronectin, Gelatin, Laminin |
| MMP-15   | MT2-MMP        | Fibronectin, Gelatin      | -                                   |
| MMP-16   | MT3-MMP        |                           | -                                   |
| MMP-17   | MT4-MMP        | Fibronectin, Gelatin      | -                                   |
| MMP-18   | Identified as MMP-19 | -                      | Aggrecan, Fibronectin, Gelatin, Laminin, COMP |
| MMP-19   | RASI-1 IV      |                           | -                                   |
| MMP-20   | Enamelysin     | Aggrecan, Amelogenin, COMP| -                                   |
| MMP-21   | X-MMP          |                           | -                                   |
| MMP-22   | C-MMP          |                           | -                                   |
| MMP-23   | Identified as MMP-23 | -                      | -                                   |
| MMP-24   | MT5-MMP        |                           | -                                   |
| MMP-25   | MT6-MMP IV     |                          | Fibronectin, Gelatin, Laminin      |
| MMP-26   | Matrilysin-2 IV|                          | Fibronectin, Gelatin               |
| MMP-27   |                |                           | -                                   |
| MMP-28   | Epilysin       |                           | -                                   |

MT: Membrane-type; COMP: Cartilage oligomeric protein.

Figure 1. Matrix metalloproteinases (MMPs) are comprised of different subdomains. Most have a minimal domain (a signal peptide, propeptide, and catalytic domain), a hinge region, and a hemopexin-like C-terminal domain. Gelatinases (MMP-2 and MMP-9) contain three repeats of a fibronectin type II motif in the catalytic domain. Membrane-type MMPs have a type I transmembrane domain/cytoplasmic domain or a glycosylphosphatidylinositol (GPI) anchor in addition. MMP-23 contains a type II transmembrane domain, a cysteine array, and an immunoglobulin-like domain. The propeptide contains a furin cleavage site (RXKR motif) in MMP-11, MMP-21, MMP-23, MMP-28, and membrane-type MMPs. MMP-7 and MMP-26 lack both a hinge region and a hemopexin-like C-terminal domain.
3. The Pathogenesis of Rheumatoid Arthritis

3.1. The Epidemiology and Etiology of RA

RA is a chronic systemic inflammatory disorder that is caused by an autoimmune response, which is characterized by the presence of anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid factors (RF) [24–27]. RA affects approximately 1% of the population worldwide and is two-to-three-fold more common in women than in men [28]. Recently, new treatments, such as antirheumatic biologics and Janus kinase (JAK) inhibitors, have been developed and have revolutionized RA therapy [29–31]. Nevertheless, randomized controlled clinical trials have demonstrated that these biologic drugs can only treat approximately 50% of RA patients successfully on average. They work via the following mechanisms: (1) TNF-α inhibition (infliximab [32–35], etanercept [36–41], adalimumab [42–44], golimumab [45–49], and certolizumab pegol [50]) [51–53]; (2) B cell depletion (rituximab [54,55]); (3) disruption of T cell co-stimulation (abatacept [56–61]); (4) IL-1 inhibition (anakinra [62]); and (5) IL-6 inhibition (tocilizumab [63–68]). The remainder of RA patients do not respond or do not fully benefit from these treatments. The therapeutic effect of the JAK inhibitor tofacitinib is similar to these antirheumatic biologics [69–73].

The pathogenesis of RA is multifactorial and has not yet been completely elucidated [74]. Recent advances have demonstrated that environmental factors trigger RA in genetically predisposed individuals, evidence for which includes a higher concordance for RA in monozygotic twins than in either dizygotic twins or non-twins [75–77], the high relative risk for RA in multiplex families [78], the association of susceptibility to RA with human leukocyte antigen (HLA)-DRB1 alleles that contain a shared epitope (which is associated with RA severity and the production of ACPA in RA) [79–81], and a number of RA risk genes identified by genome-wide association studies (GWAS), such as PTPN22 (protein tyrosine phosphatase, non-receptor type 22), STAT4, CCR6 (chemokine receptor 6), TNFAIP3 (TNF-α-induced protein 3), PADI4 (peptidyl arginine deiminase 4), CD40 (cluster of differentiation 40), and FCRL3 (Fc receptor-like protein 3) [82,83]. Conversely, certain environmental factors, including cigarette smoking [84,85], Epstein–Barr virus (EBV) infection [86,87], periodontitis caused by Porphyromonas gingivalis [88,89], sex hormones [90,91], vitamin D deficiency [92,93], and silica exposure [94], have been shown to be associated with the pathogenesis of RA. In addition, recent advances have indicated that epigenetic mechanisms are associated with the etiology of RA [95,96].

3.2. The Pathological Roles of MMPs in RA

RA is characterized by progressive joint destruction with loss of bone and cartilage as well as the aggressive activation of SFs bearing a tumor-like appearance [97–99]. MMPs play a critical role in the pathogenesis of RA [20]. RASFs secrete various proteases, including MMPs that degrade ECM components, mainly proteoglycans and collagens, of articular cartilage in the affected joints [100]. Since MMP-1, MMP-3, MMP-9, and MMP-13 expression is upregulated in RASFs, MMPs are considered to play a critical role in the degeneration of cartilage in RA joints [17]. MMP-1 (collagenase 1) and MMP-13 (collagenase 3) cleave collagens, whereas MMP-3 (stromelysin 1) and MMP-9 (gelatinase B) target proteoglycans that are comprised of aggrecan. The degeneration of proteoglycans at the surface and the subsequent degradation of collagen fibrils in the deep zone together result in the destruction of articular cartilage. MMPs may thus play a distinct role in joint destruction in RA.

MMPs are potent markers for predicting the functional and radiographic outcome of joints in RA. The serum concentrations of MMP-1 and MMP-3 correlate with disease activity and predict the progression of joint destruction in RA [101–103]. Treatment with disease-modifying antirheumatic drugs (DMARDs) and antirheumatic biologics significantly downregulates the serum levels of MMP-1 and MMP-3 in parallel with the reduction in disease activity [104,105].

It has been shown that MT1-MMP (MMP-14) is the major MMP that is associated with cartilage invasion by RA synovial tissues/RASFs. MT1-MMP is highly expressed at the junction of pannus and cartilage and is responsible for the invasion of RASFs into cartilage [106]. MT1-MMP is involved in not
only ECM remodeling but also the angiogenic response that plays an important role in the aggressive phenotype of RASFs [107]. Treatment with an MT1-MMP selective inhibitory antibody suppresses both cartilage destruction and disease progression in a collagen-induced arthritis (CIA) mouse model [108].

Several studies have focused on the phenotype of MMP-deficient mice. MMP-8-deficient mice have been backcrossed onto a Fas-defective MRL/lpr background that is characterized by spontaneous arthritis [109]. The mice showed earlier and more severe arthritis as well as an increase in neutrophil infiltration due to delayed apoptosis. Therefore, MMP-8 is considered to be anti-inflammatory. To examine whether gelatinases (MMP-2 and MMP-9) play an important role in RA, the development of antibody-induced arthritis in MMP-2 or MMP-9-deficient mice has been investigated [110]. MMP-2-deficient mice show severe arthritis, whereas MMP-9-deficient mice exhibit mild arthritis. These findings suggest a suppressive role for MMP-2 and a pivotal role of MMP-9 in arthritis. MMP-3-deficient mice develop arthritis in a CIA model [111], and disruption of MMP-3 gene does not prevent cartilage destruction.

Over the past decade, antirheumatic biologics and JAK inhibitors have been developed as effective drugs for RA. Because the agents still have several issues, including inadequate efficacy, infection risk, and cost, it has been expected that alternative therapies for RA will appear. MMPs are considered an important novel therapeutic target in RA because they are thought to be harmful in the disease. Pharmaceutical companies have thus synthesized small molecule MMP inhibitors [20], some of which have entered clinical trials for RA therapy [112,113]. For example, cipemastat, a selective inhibitor of collagenases (MMP-1, MMP-8, and MMP-13), is reportedly well tolerated with no serious adverse events [114,115]. It was expected to be a promising agent for RA therapy given results of animal models of arthritis [116,117]. However, the compound did not prevent progression of joint destruction in RA patients in phase III trials [118,119]. Clinical trials of all of other MMP inhibitors have also thus far been unsuccessful, and pharmaceutical companies have halted their development. There are several reasons why these clinical trials failed. Because MMP inhibitors target the catalytic sites of the enzymes, their specificity has been low. Furthermore, MMPs are not necessarily harmful in arthritic diseases. Some MMPs, including MMP-2 and MMP-8, exhibit protective effects against arthritic diseases as discussed above. At present, there are still several potentially good MMP inhibitors, such as a highly selective inhibitor of MMP-13 [120] and a humanized inhibitory antibody against MT1-MMP [108]. Further preclinical and clinical research is needed for the development of these novel inhibitors as useful therapeutics for RA.

The adamalysins, including ADAMs (a disintegrin and metalloproteinase) and ADAMTSs (ADAMs with thrombospondin motifs), are a family of membrane-associated zinc-dependent metallo exopeptidases that degrade ECM components [121]. Twenty-four ADAMs have been identified in humans and are implicated in reproductive processes. ADAM-17, known as TNF-α converting enzyme (TACE), cleaves the proform of TNF-α into its active form [122,123]. In addition, 18 ADAMTSs have been described in humans and are associated with pathological processes. ADAMTS-4 and ADAMTS-5/11 are aggrecanase-1 and aggrecanase-2, respectively, which are involved in cartilage destruction in arthritic diseases [124–128].

4. Epigenetic Mechanisms

4.1. Epigenetics and Chromatin Structure

Epigenetics is a relatively new area of research, first proposed by Waddington, in which gene regulation mediated by mutations modulates development. Subsequently, it was defined as a stably heritable phenotype resulting from changes in a chromosome without alterations in the DNA sequence [129]. Epigenetic changes are transmitted during the process of either mitosis or meiosis. Several major epigenetic mechanisms have been identified to date, including post-translational histone modifications, DNA methylation, and the expression of non-coding RNAs (ncRNAs) such as miRNAs [130]. These mechanisms determine the specific chromatin structure and consequently
influence gene expression independently of the DNA sequence. Chromatin is a structure in which DNA is tightly packaged in the nuclei of eukaryotic cells [131]. The nucleosome is the fundamental subunit of chromatin and is composed of 147 bp of DNA wrapped around an octamer of the four core histones (H2A, H2B, H3, and H4). The chromatin state in DNA-regulating regions, such as promoters and enhancers, determines the accessibility for TFs and consequently affects gene transcription. The chromatin state is classified into two basic forms: euchromatin is an open state in which TFs can bind to promoters and activate genes, whereas heterochromatin is a closed state in which TFs are unable to reach promoters and genes are silent.

Genome-wide analyses of histone methylation and gene expression have elucidated four distinct forms of association, namely repressed, active, poised, and bivalent [132–134]. In repressed genes, heterochromatin suppresses gene transcription. In active genes, euchromatin activates gene transcription. In poised genes, euchromatin does not activate gene transcription while at rest; however, stimulation with certain factors such as cytokines induces gene activation rapidly. In bivalent genes, the chromatin contains both active and repressive histone markers. Chromatin is able to convert into euchromatin or heterochromatin either through cell differentiation or upon activation.

4.2. Histone Modifications

The histone code hypothesis that Strahl and Allis proposed means that multiple histone modifications, acting in a combinatorial or sequential fashion on one or multiple histone tails, specify unique downstream functions [135]. Histone tails are subject to covalent post-translational modifications, including methylation, acetylation, ubiquitination and phosphorylation, that regulate whether genes are in a transcriptionally active or silent chromatin state (Figure 2) [136–139]. The modifications are markers that reflect both the chromatin state and gene transcription status. Active histone markers, which are located on euchromatin and activate gene transcription, include acetylation—H2A lysine 5 (H2AK5), H2AK9, H2AK13, H2AK15, H2BK5, H2BK12, H2BK15, H2BK20, H2BK120, H3K4, H3K9, H3K14, H3K18, H3K23, H3K27, H3K36, H4K5, H4K8, H4K12, H4K16, H4K20, and H4K91—, methylation—H2BK5, H3 arginine 2 (H3R2), H3K4, H3R8, H3K9, H3R17, H3R26, H3K27, H3K36, H3K79, H4R3, and H4K20—, phosphorylation—H2A serine 1 (H2AS1), H2BS14, H3 threonine 3 (H3T3), H3S10, H3T11, H3S28, and H4S1—, and ubiquitination (H2AK119, H2BK120). Repressive histone markers, which exist on heterochromatin and suppress gene transcription, include methylation (H3K9, H3K27, and H4K20), ubiquitination (H2AK119), and sumoylation (H2AK126, H2BK6, and H2BK7). A complex combination of these histone modifications controls chromatin states and gene transcription. The regulation of the chromatin state by combinatorial patterns of histone acetylation and methylation has been demonstrated in a genome-wide analysis [140].

To date, histone methylation and acetylation have been well studied. Histone methyltransferases (HMTs) transfer methyl groups, whereas histone demethylases (HDMs) remove methyl groups [141,142]. HMTs and HDMs specifically catalyze particular lysine or arginine residues [143,144]. The functions of histone methylation are defined by both the methylated residue and the number of methyl groups [145,146]. Histone acetyltransferases (HATs) add acetyl groups to lysine residues, resulting in gene activation [147,148]. Histone deacetylases (HDACs) remove acetyl groups from lysine residues, leading to gene silencing [149,150].

Disordered histone modifications in MMP genes have been demonstrated in several diseases, such as cervical cancer and cardiovascular diseases. HDAC10 represses the expression of MMP-2 and MMP-9, which are involved in cancer cell invasion and metastasis [151]. The expression level of HDAC10 is low in patients exhibiting lymph node metastasis in cervical squamous cell carcinoma. In addition, HDAC10 binds to MMP-2 and MMP-9 promoters and decreases histone acetylation levels. Post-myocardial infarction induction of MMP-9 causes deleterious effects on the left ventricle and ECM remodeling in the myocardial infarction region [152]. MMP-9 upregulation is associated with an increase in histone acetylation by HATs.
Figure 2. Histone modifications, including methylation, acetylation, ubiquitination, phosphorylation, and sumoylation have a variety of biological functions, including the regulation of chromatin states and gene transcription.

4.3. DNA Methylation

DNA methylation is a process in which the carbon at the 5′ position of cytosine is methylated (5mC) (Figure 3). DNA methylation in mammals is generated in CpG dinucleotides that are generally clustered in the promoters of genes (CpG islands). A high degree of DNA methylation blocks the association of TFs and results in gene silencing, whereas a lack of DNA methylation permits TF binding and leads to gene activation. It is possible that DNA methylation in other regions, such as the gene body, is associated with an increase in gene expression. DNA methylation also plays an important role in suppressing the expression of potentially harmful transposable and viral elements in genomes. DNA methylation is catalyzed by DNA methyltransferases (DNMTs), including de novo methyltransferases (DNMT3A, DNMT3B) and a maintenance methyltransferase DNMT1. The former enzymes add a methyl group to unmethylated or hemimethylated CpG sites, giving rise to new DNA methylation regions. The latter enzyme adds a methyl group to hemimethylated CpG sites in daughter strands during cell division, maintaining the methylation patterns throughout the course of cell replication. Although DNA methylation was generally considered stable, recent studies have shown that methylation can be erased by both passive and active mechanisms. Passive DNA demethylation is caused by a decrease in DNMT activity during cell division, which gradually reduces methylation. Active DNA demethylation is catalyzed by the ten-eleven translocation (TET) family of enzymes (TET1, TET2, and TET3), which convert 5mC into 5-hydroxymethylcytosine (5hmC). Further, TET enzymes exchange 5hmC for 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). An unmethylated cytosine is generated either through a replication dependent dilution of 5hmC or the removal of either 5fC or 5caC by thymine DNA glycosylate (TDG)-mediated base excision repair.

Disordered DNA methylation in MMP genes has been reported in several diseases, such as diabetes, cerebral ischemic stroke, and periapical inflammation. Activated MMP-9 is involved in the development of diabetic retinopathy [153]. In the MMP-9 promoter in diabetic retinal endothelial cells, 5mC levels are decreased, whereas TET2 binding and 5hmC levels are increased. MMP-2 activity is increased in cerebral ischemic stroke [154]. DNA methylation levels of the MMP-2 gene in the peripheral blood of patients with stroke are lower than in controls. High MMP-9 mRNA expression
and low DNA methylated profiles of the MMP-9 gene have been found in periapical inflammatory lesions [155]. This indicates a critical role for DNA methylation in periapical inflammation.

**Figure 3.** DNA methylation and demethylation are catalyzed by DNA methyltransferases (DNMTs) and ten-eleven translocation (TET) enzymes, respectively. Cytosine at CpG sites is methylated by DNMTs to yield 5-methylcytosine (5mC). The 5mC is hydroxylated by TET enzymes to yield 5-hydroxymethylcytosine (5hmC), which in turn is oxidized to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC). The 5fC and 5caC are converted to unmethylated C by thymine DNA glycosylate (TDG)-mediated base excision repair.

### 4.4. miRNAs

Mature miRNAs are short single-stranded ncRNAs (19–25 nucleotides) that are associated with one or more mRNAs and cause gene silencing through mRNA cleavage or translational repression (Figure 4) [156–158]. miRNAs are encoded in the genome and are transcribed to long primary miRNAs (pri-miRNAs) of several kb in length by RNA polymerase II. Several miRNA genes exist as clusters and are generated from common pri-miRNAs. In the nucleus, Drosha processes the pri-miRNAs into 60–80-nucleotide short precursor miRNAs (pre-miRNAs) that have a hairpin structure. Alternatively, a few miRNAs are present in introns (known as “mitrons”), which become lariat products after splicing. A lariat-debranching enzyme liberates the resulting products to yield pre-miRNAs. The nuclear export protein exportin 5 (EXP-5) exports pre-miRNAs to the cytoplasm. In the cytoplasm, the RNase III-type enzyme Dicer (DCR-1) cleaves the pre-miRNAs to generate a duplex containing two guide and passenger strands. Perfect complementarity between miRNAs and the mRNA targets results in the cleavage of the mRNA strands, whereas imperfect complementarity leads to translational repression.

Disordered miRNA expression that leads to aberrant MMP gene expression has been shown in several diseases. Downregulation of miR-29b-3p increases MMP-2 expression in arterial calcification [159]. Downregulation of miR-376c enhances MMP-2 expression in prostate cancer bone metastasis [160]. Decreases in miR-133a, miR-27b, and miR-155 upregulate MMP-9, MMP-13, and MMP-16 expression, respectively, resulting in intervertebral disc degeneration [161–163]. Reduced miR-106b expression causes breast cancer cell invasion through the upregulation of MMP-2 [164].
Figure 4. MicroRNAs (miRNAs) are initially transcribed as long primary miRNA (pri-miRNA) and cleaved by Drosha to yield a short precursor miRNA (pre-miRNA) in the nucleus. After export to the cytoplasm, the pre-miRNA is processed by Dicer to yield a double stranded-miRNA complex. Following the association with the RNA-induced silencing complex (RISC) and the removal of the complementary strand, a mature miRNA cleaves a target mRNA or represses its translation. Ago: Argonaute; m\textsuperscript{7} G: RNA 7-methylguanosine cap.

5. Epigenetic Mechanisms Regulating MMP Transcription in RA

5.1. Disordered Histone Modifications in MMP Genes in RA

Disordered histone methylation gives rise to active chromatin states in MMP genes in RASFs. The active histone marker H3K4me3 increases, while the repressive histone marker H3K27me3 decreases in the promoters of MMP-1, MMP-3, MMP-9 and MMP-13 in RASFs [17]. WD (Trp–Asp) repeat domain 5 (WDR5) is a core subunit of complex proteins associated with SET1 (Su(var)3-9, Enhancer-of-zeste and Trithorax 1) (COMPASS) as well as COMPASS-like complexes that methylate H3K4 [165]. WDR5 knockdown downregulates not only the levels of H3K4me3, but also the expression of MMP-1, MMP-3, MMP-9 and MMP-13 in RASFs; H3K4me3 has been suggested to regulate spontaneous MMP gene transcription in RASFs. IL-6 signaling increases the expression of MMP-1,
MMP-3 and MMP-13, but not MMP-9, despite the active chromatin states in all of these promoters in RASFs. The IL-6-induced transcription factor STAT3 is associated with the MMP-1, MMP-3 and MMP-13 promoters, but not the MMP-9 promoter. It has been suggested that the difference in response to IL-6 signaling in MMP genes is caused by STAT3 binding to their promoters. The binding of STAT3 to MMP-1, 3 and 13 promoters upregulates gene transcription, whereas the inaccessibility of STAT3 in the MMP-9 promoter does not allow gene activation. Aberrant histone methylation and the binding of STAT3 to the promoters differentially regulate constitutive and IL-6-induced gene expression of MMP-1, MMP-3, MMP-9 and MMP-13 in RASFs.

It is possible that disordered histone-modifying enzymes, including HMTs, HDMs, HATs and HDACs, disrupt histone modifications in RA. An H3K27-catalyzing HMT, enhancer of zeste homologue 2 (EZH2), is highly expressed in RASFs and induced by TNF-α through the NF-κB and Jun kinase pathways [166]. Secreted fizzled-related protein 1 (SFRP1), an inhibitor of Wnt signaling, has been identified as the target gene of EZH2 and is associated with the activation of RASFs.

5.2. Disordered DNA Methylation in MMP Genes in RA

Low levels of global DNA methylation have been demonstrated in both RA synovial tissues and RASFs [167]. Proliferating RASFs have been shown to be deficient in DNMT1 expression. The 5-azacytidine (5-azaC), an inhibitor of DNMTs, provides normal SFs with the activated phenotype of RASFs. The resulting DNA hypomethylation upregulates the expression of 186 genes, including MMP-1 and MMP-14. Although both DNMTs and TET enzymes might disrupt DNA methylation in RA, it remains unknown whether TET enzymes are involved in the pathogenesis of RA. Disordered DNA methylation-catalyzing enzymes may affect the expression of various genes, including MMP genes.

5.3. Disordered miRNA Expression in MMP Genes in RA

Microarray analysis has shown that both miR-155 and miR-146a are highly expressed in RASFs [168]. The overexpression of miR-155 represses MMP-3 expression and reduces the induction of MMP-1 and MMP-3 by Toll-like receptor (TLR) ligands and cytokines in RASFs. miR-155 possibly has a counter-regulatory role in the process of joint destruction in RA. miR-155 might function as a protective miRNA that locally suppresses MMP expression and thereby blocks excessive tissue damage by inflammation. The same group examined differentially expressed miRNAs in RASFs by screening 260 miRNAs [169]. As a result, miR-203 was found to be highly expressed in RASFs. As DNA demethylation with 5-azaC has been shown to upregulate miR-203 expression, this miRNA is regulated by DNA methylation. The overexpression of miR-203 significantly enhances MMP-1 production. Another microarray analysis demonstrated that miR-155 expression is increased and can be induced by TNF-α in RASFs [170]. The enforced expression of miR-155 decreases MMP-3 expression in RASFs. Inhibitor of κ light polypeptide gene enhancer in B-cells, kinase ε (IKBKE) increases the production of MMP-3 and MMP-13 by TNF-α, IL-1β and lipopolysaccharide (LPS) through c-Jun phosphorylation in RASFs [171]. IKBKE has been shown to be a target of miR-155. It has been suggested that miR-155 may be a protective factor against inflammation by attenuating the expression of IKBKE in RASFs. Another microarray analysis revealed that miR-19b is downregulated in RASFs [172]. The overexpression of miR-19b decreases the expression of MMP-3, and has been suggested to function as a negative regulator of inflammation in RA.

6. Conclusions

MMPs are produced by RASFs and play a crucial role in cartilage destruction in the inflamed joints in RA. Therefore, understanding the mechanisms regulating MMP expression is critical for developing RA therapeutics. Recently, substantial and accumulating data on epigenetic dysregulation has emerged in RA. Disorders of epigenetic regulation, including histone modifications, DNA methylation and miRNA signaling, are involved in the upregulation of MMP expression in RASFs. Further study is needed to elucidate the crosstalk among these different epigenetic mechanisms. It is hoped that
advanced knowledge of the epigenetic mechanisms that control MMP gene activation in RASFs will provide a better understanding of the pathogenesis of RA and help develop new therapeutic strategies for this pernicious disease.

Acknowledgments: This work was supported by JSPS KAKENHI Grant Numbers 16K09903 (to Yasuto Araki) and 16K09902 (to Toshihide Mimura), by Grant-in Aid for Young researchers (28-E-1-05) from Saitama Medical University Hospital (to Yasuto Araki), and by the Practical Research Project for Rare/Intractable Diseases (15ek010919h0002) from Japan Agency for Medical Research and development, AMED (to Toshihide Mimura). The authors appreciate Natsuko Kurosawa for her help in preparing figures.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Marino, G.; Uria, J.A.; Puente, X.S.; Quesada, V.; Bordallo, J.; Lopez-Otin, C. Human autophagins, a family of cysteine proteinases potentially implicated in cell degradation by autophagy. J. Biol. Chem. 2003, 278, 3671–3678. [CrossRef] [PubMed]
2. Ciechanover, A. Proteolysis: From the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 2005, 6, 79–87. [CrossRef] [PubMed]
3. Siegel, R.M. Caspases at the crossroads of immune-cell life and death. Nat. Rev. Immunol. 2006, 6, 308–317. [CrossRef] [PubMed]
4. Oikonomopoulou, K.; Hansen, K.K.; Saifeddine, M.; Vergnolle, N.; Tea, I.; Diamandis, E.P.; Hollenberg, M.D. Proteinase-mediated cell signalling: Targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol. Chem. 2006, 387, 677–685. [CrossRef] [PubMed]
5. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221–233. [CrossRef] [PubMed]
6. Lopez-Otin, C.; Matrisian, L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7, 800–888. [CrossRef] [PubMed]
7. Lopez-Otin, C.; Bond, J.S. Proteases: Multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283, 30433–30437. [CrossRef] [PubMed]
8. Drag, M.; Salvesen, G.S. Emerging principles in protease-based drug discovery. Nat. Rev. Drug Discov. 2010, 9, 690–701. [CrossRef] [PubMed]
9. Turk, B. Targeting proteases: Successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5, 785–799. [CrossRef] [PubMed]
10. Turk, B.; Turk, D.; Turk, V. Protease signalling: The cutting edge. EMBO J. 2012, 31, 1630–1643. [CrossRef] [PubMed]
11. Lopez-Otin, C.; Overall, C.M. Protease degradomics: A new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 2002, 3, 509–519. [CrossRef] [PubMed]
12. Overall, C.M.; Blobel, C.P. In search of partners: Linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 2007, 8, 245–257. [CrossRef] [PubMed]
13. Martel-Pelletier, J.; Welsch, D.J.; Pelletier, J.P. Metalloproteases and inhibitors in arthritic diseases. Best Pract. Res. Clin. Rheumatol. 2001, 15, 805–829. [CrossRef] [PubMed]
14. Choy, E.H.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344, 907–916. [PubMed]
15. Yan, C.; Boyd, D.D. Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol. 2007, 211, 19–26. [CrossRef] [PubMed]
16. Wada, T.T.; Araki, Y.; Sato, K.; Aizaki, Y.; Yokota, K.; Kim, Y.T.; Oda, H.; Kurokawa, R.; Mimura, T. Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem. Biophys. Res. Commun. 2014, 444, 682–686. [CrossRef] [PubMed]
17. Araki, Y.; Tsuzuki Wada, T.; Aizaki, Y.; Sato, K.; Yokota, K.; Fujimoto, K.; Kim, Y.T.; Oda, H.; Kurokawa, R.; Mimura, T. Histone methylation and STAT-3 differentially regulate interleukin-6-induced matrix metalloproteinase gene activation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheumatol. 2016, 68, 1111–1123. [PubMed]
18. Rengel, Y.; Ospelt, C.; Gay, S. Proteinases in the joint: Clinical relevance of proteinases in joint destruction. Arthritis Res. Ther. 2007, 9, 221. [CrossRef] [PubMed]
Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. *Cell* **2010**, *141*, 52–67. [CrossRef] [PubMed]

Itoh, Y. Metalloproteinases: Potential therapeutic targets for rheumatoid arthritis. *Endocr. Metab. Immune Disord. Drug Targets* **2015**, *15*, 216–222. [CrossRef] [PubMed]

Overall, C.M.; Lopez-Otin, C. Strategies for MMP inhibition in cancer: Innovations for the post-trial era. *Nat. Rev. Cancer* **2002**, *2*, 657–672. [CrossRef] [PubMed]

Morrison, C.J.; Overall, C.M. TIMP independence of matrix metalloproteinase (MMP)-2 activation by membrane type 2 (MT2)-MMP is determined by contributions of both the MT2-MMP catalytic and hemopexin C domains. *J. Biol. Chem.* **2006**, *281*, 26528–26539. [CrossRef] [PubMed]

Shofuda, K.; Yasumitsu, H.; Nishihashi, A.; Miki, K.; Miyazaki, K. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. *J. Biol. Chem.* **1997**, *272*, 9749–9754. [PubMed]

Firestein, G.S. Evolving concepts of rheumatoid arthritis. *Nature* **2003**, *423*, 356–361. [PubMed]

Sakkas, L.I.; Bogdanos, D.P.; Katsiari, C.; Platsoucas, C.D. Anti-citrullinated peptides as autoantigens in rheumatoid arthritis-relevance to treatment. *Autoimmun. Rev.* **2014**, *13*, 1114–1120. [PubMed]

Hardy, R.R.; Hayakawa, K.; Shimizu, M.; Yamasaki, K.; Kishimoto, T. Rheumatoid factor secretion from human Leu-1+ B cells. *Science* **1987**, *236*, 81–83. [PubMed]

Tan, E.M.; Smolen, J.S. Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. *J. Exp. Med.* **2016**, *213*, 1937–1950. [PubMed]

Gibofsky, A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis. *Am. J. Manag. Care* **2014**, *20*, S128–S135. [PubMed]

Nam, J.L.; Ramiro, S.; Gaujoux-Viala, C.; Takase, K.; Leon-Garcia, M.; Emery, P.; Gossec, L.; Landewe, R.; Smolen, J.S.; Buch, M.H. Efficacy of biological disease-modifying antirheumatic drugs: A systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann. Rheum. Dis.* **2014**, *73*, 516–528. [PubMed]

Wang, D.; Li, Y.; Liu, Y.; Shi, G. The use of biologic therapies in the treatment of rheumatoid arthritis. *Curr. Pharm. Biotechnol.* **2014**, *15*, 542–548. [CrossRef] [PubMed]

Tanaka, Y.; Yamaoka, K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: From basic to clinical. *Mod. Rheumatol.* **2013**, *23*, 415–424. [CrossRef] [PubMed]

Lipsky, P.E.; van der Heijde, D.M.; St. Clair, E.W.; Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Weisman, M.; Emery, P.; Feldmann, M.; et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: A randomised phase III trial. * ATTRACT Study Group. Lancet* **1999**, *354*, 1932–1939. [CrossRef]

St Clair, E.W.; van der Heijde, D.M.; Smolen, J.S.; Maini, R.N.; Bathon, J.M.; Emery, P.; Keystone, E.; Schiff, M.; Feldmann, M.; et al. Combination of infliximab and methotrexate for early rheumatoid arthritis: A randomized, controlled trial. *Arthritis Rheum.* **2004**, *50*, 3432–3443. [CrossRef] [PubMed]

Larry, W.; Moreland, M.D.; Scott, W.; Baumgartner, M.D.; Michael, H.; Schiff, M.D.; Elizabeth, A.; Tindall, M.D.; Roy, M.; Fleischmann, M.D.; et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N. Engl. J. Med.* **1997**, *337*, 141–147.

Moreland, L.W.; Schiff, M.H.; Baumgartner, S.W.; Tindall, E.A.; Fleischmann, R.M.; Bulpitt, K.J.; Weaver, A.L.; Keystone, E.C.; Furst, D.E.; Mease, P.J.; et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann. Intern. Med.* **1999**, *130*, 478–486. [CrossRef] [PubMed]
38. Michael, E.; Weinblatt, M.D.; Joel, M.; Kremer, M.D.; Arthur, D.; Bankhurst, M.D.; Ken, J.; Bulpitt, M.D.; Roy, M.; Fleischmann, M.D.; et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N. Engl. J. Med.* 1999, 340, 253–259.

39. Bathon, J.M.; Martin, R.W.; Fleischmann, R.M.; Tesser, J.R.; Schiff, M.H.; Keystone, E.C.; Genovese, M.C.; Wasko, M.C.; Moreland, L.W.; Weaver, A.L.; et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N. Engl. J. Med.* 2000, 343, 1586–1593. [CrossRef] [PubMed]

40. Genovese, M.C.; Bathon, J.M.; Martin, R.W.; Fleischmann, R.M.; Tesser, J.R.; Schiff, M.H.; Keystone, E.C.; Wasko, M.C.; Moreland, L.W.; Weaver, A.L.; et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. *Arthritis Rheum.* 2002, 46, 1443–1450. [CrossRef] [PubMed]

41. Emery, P.; Breedveld, F.C.; Hall, S.; Durez, P.; Chang, D.J.; Robertson, D.; Singh, A.; Pedersen, R.D.; Koenig, A.S.; Freundlich, B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. *Lancet* 2008, 372, 375–382. [CrossRef]

42. Weinblatt, M.E.; Keystone, E.C.; Forst, D.E.; Moreland, L.W.; Weisman, M.H.; Birbara, C.A.; Fischkoff, S.A.; Chartash, E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. *Arthritis Rheum.* 2003, 48, 35–45. [CrossRef] [PubMed]

43. Keystone, E.C.; Kavanaugh, A.F.; Sharp, J.T.; Tannenbaum, H.; Huá, Y.; Teoh, L.S.; Fischkoff, S.A.; Chartash, E.K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monomeric antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. *Arthritis Rheum.* 2004, 50, 1400–1411. [PubMed]

44. Breedveld, F.C.; Weisman, M.H.; Kavanaugh, A.F.; Cohen, S.B.; Pavelka, K.; van Vollenhoven, R.; Sharp, J.; Perez, J.L.; Spencer-Green, G.T. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum.* 2006, 54, 26–37. [PubMed]

45. Kay, J.; Matteson, E.L.; Dasgupta, B.; Nash, P.; Durez, P.; Hall, S.; Hsia, E.C.; Han, J.; Wagner, C.; Xu, Z.; et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. *Arthritis Rheum.* 2008, 58, 964–975. [CrossRef] [PubMed]

46. Keystone, E.C.; Genovese, M.C.; Klareskog, L.; Hsia, E.C.; Hall, S.T.; Miranda, P.C.; Pazdur, J.; Bae, S.C.; Palmer, W.; Zrubek, J.; et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD Study. *Ann. Rheum. Dis.* 2009, 68, 789–796. [CrossRef] [PubMed]

47. Keystone, E.; Genovese, M.C.; Klareskog, L.; Hsia, E.C.; Hall, S.; Miranda, P.C.; Pazdur, J.; Bae, S.C.; Palmer, W.; Xu, S.; et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled study. *Arthritis Rheum.* 2010, 62, 1129–1135. [CrossRef] [PubMed]

48. Emery, P.; Fleischmann, R.M.; Moreland, L.W.; Hsia, E.C.; Strusberg, I.; Durez, P.; Nash, P.; Amante, E.J.; Churchill, M.; Park, W.; et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum.* 2009, 60, 2272–2283. [PubMed]

49. Kremer, J.; Ritchlin, C.; Mendelsohn, A.; Baker, D.; Kim, L.; Xu, Z.; Han, J.; Taylor, P. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. *Arthritis Rheum.* 2010, 62, 917–928. [CrossRef] [PubMed]

50. Keystone, E.; van der Heijde, D.; Mason, D.; Landewe, R., Jr.; Vollenhoven, R.R.; Combe, B.; Emery, P.; Strand, V.; Mease, P.; Desai, C.; et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum.* 2008, 58, 3319–3329. [CrossRef] [PubMed]
51. Smolen, J.; Landewe, R.R.; Mease, P.; Brzezicki, J.; Mason, D.; Luijten, K.; van Vollenhoven, R.F.; Kavanaugh, A.; Schiff, M.; Burmester, G.R.; et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 2009, 68, 797–804. [CrossRef] [PubMed]

52. Fleischmann, R.; Vencovsky, J.; van Vollenhoven, R.R.; Borenstein, D.; Box, J.; Coteur, G.; Goel, N.; Brezinschek, H.P.; Innes, A.; Strand, V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in 5 patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann. Rheum. Dis. 2009, 68, 805–811. [CrossRef] [PubMed]

53. Choy, E.E.; Hazleman, B.; Smith, M.; Moss, K.; Lisi, L.; Scott, D.G.; Patel, J.; Sopwith, M.; Isenberg, D.A. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology 2002, 41, 1133–1137. [CrossRef] [PubMed]

54. Edwards, J.J.; Szczepanski, L.; Szechinski, J.; Filipowicz-Sosnowska, A.; Emery, P.; Close, D. R.; Stevens, R.M.; Shaw, T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004, 350, 2572–2581. [CrossRef] [PubMed]

55. Cohen, S.S.; Emery, P.; Greenwald, M.M.; Dougdas, M.; Furie, R.R.; Genovese, M.C.; Keystone, E.C.; Loveless, J.E.; Burmester, G.R.; Cravets, M.W.; et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006, 54, 2793–2806. [CrossRef] [PubMed]

56. Kremer, J.J.; Westhovens, R.; Leon, M.; Di Giorgio, E.; Alten, R.; Steinfeld, S.; Russell, A.; Dougdas, M.; Emery, P.; Nuamah, I.F.; et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003, 349, 1907–1915. [CrossRef] [PubMed]

57. Kremer, J.J.; Genant, H.H.; Moreland, L.L.; Russell, A.A.; Emery, P.; Abud-Mendoza, C.; Szechinski, J.; Li, T.; Ge, Z.; Becker, J.C.; et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 2006, 144, 865–876. [CrossRef] [PubMed]

58. Genovese, M.M.; Becker, J.J.; Schiff, M.; Luggen, M.; Sherrer, Y.; Kremer, J.; Birbara, C.; Box, J.; Natarajan, K.; et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005, 353, 1114–1123. [CrossRef] [PubMed]

59. Kremer, J.J.; Genant, H.H.; Moreland, L.L.; Russell, A.A.; Emery, P.; Abud-Mendoza, C.; Szechiński, J.; Li, T.; Teng, J.; Becker, J.C.; et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008, 58, 953–963. [CrossRef] [PubMed]

60. Kremer, J.J.; Dougdas, M.; Emery, P.; Durez, P.; Sibilia, J.; Shergy, W.; Steinfeld, S.; Tindall, E.; Becker, J.C.; Li, T.; et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005, 52, 2262–2271. [CrossRef] [PubMed]

61. Westhovens, R.; Robles, M.; Ximenes, A.A.; Nayiager, S.; Wollenhaupt, J.; Durez, P.; Gomez-Reino, J.; Grassi, W.; Harauoi, B.; Shergy, W.; et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009, 68, 1870–1877. [CrossRef] [PubMed]

62. Bresnihan, B.; Alvaro-Gracia, J.J.; Cobby, M.; Doherty, M.; Domljan, Z.; Emery, P.; Nuki, G.; Pavelka, K.; Rau, R.; Rozman, B.; et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41, 2196–2204. [CrossRef]

63. Maini, R.R.; Taylor, P.P.; Szechinski, J.; Pavelka, K.; Broll, J.; Balint, G.; Emery, P.; Raemen, F.; Petersen, J.; Smolen, J.; et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006, 54, 2817–2829. [CrossRef] [PubMed]

64. Smolen, J.J.; Beaulieu, A.; Rubbert-Roth, A.; Ramos-Remus, C.; Rovensky, J.; Alecock, E.; Woodworth, T.; Alten, R.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008, 371, 987–997. [CrossRef]
65. Emery, P.; Keystone, E.; Tony, H.H.; Cantagrel, A.; van Vollenhoven, R.; Sanchez, A.; Alecock, E.; Lee, J.; Kremer, J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. *Ann. Rheum. Dis.* 2008, **67**, 1516–1523. [CrossRef] [PubMed]

66. Genovese, M.M.; McKay, J.J.; Nasonov, E.E.; Mysler, E.E.; da Silva, N.N.; Alecock, E.; Woodworth, T.; Gomez-Reino, J.J. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum.* 2008, **58**, 2968–2980. [PubMed]

67. Jones, G.; Sebba, A.; Gu, J.; Lowenstein, M.M.; Calvo, A.; Gomez-Reino, J.J.; Siri, D.A.; Tomsic, M.; Alecock, E.; Woodworth, T.; et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. *Ann. Rheum. Dis.* 2010, **69**, 88–96. [CrossRef] [PubMed]

68. Kremer, J.J.; Blanco, R.; Brzosko, M.; Burgos-Vargas, R.; Halland, A.A.; Vernon, E.; Ambs, P.; Fleischmann, R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis Rheum.* 2011, **63**, 609–621. [PubMed]

69. Fleischmann, R.; Kremer, J.; Cush, J.; Schulze-Koops, H.; Connell, C.C.; Bradley, J.D.; Gruben, D.; Wallenstein, G.V.; Zwillich, S.H.; et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N. Engl. J. Med.* 2012, **367**, 495–507. [CrossRef] [PubMed]

70. Van Vollenhoven, R.R.; Fleischmann, R.; Cohen, S.; Lee, E.E.; Garcia Mejide, J.J.; Wagner, S.; Foreijtova, S.; Zwillich, S.H.; Gruben, D.; Koncz, T.; et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N. Engl. J. Med.* 2012, **367**, 508–519. [CrossRef] [PubMed]

71. Van der Heijde, D.; Tanaka, Y.; Fleischmann, R.; Keystone, E.; Kremer, J.; Zerbini, C.; Cardiel, M.H.; Cohen, S.; Nash, P.; Song, Y.W.; et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum.* 2013, **65**, 559–570. [CrossRef] [PubMed]

72. Burmester, G.G.; Blanco, R.; Charles-Schoeman, C.; Wollenhaupt, J.; Zerbini, C.; Benda, B.; Gruben, D.; Wallenstein, G.; Krishnaswami, S.; Zwillich, S.H.; et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. *Lancet* 2013, **381**, 451–460. [CrossRef]

73. Kremer, J.; Li, Z.Z.; Hall, S.; Fleischmann, R.; Genovese, M.; Martin-Mola, E.; Isaacs, J.D.; Gruben, D.; Wallenstein, G.; Krishnaswami, S.; et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. *Ann. Intern. Med.* 2013, **159**, 253–261. [CrossRef] [PubMed]

74. McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. *N. Engl. J. Med.* 2011, **365**, 2205–2219. [CrossRef] [PubMed]

75. Aho, K.; Koskenvuo, M.; Tuominen, J.; Kaprio, J. Occurrence of rheumatoid arthritis in a nationwide series of twins. *J. Rheumatol.* 1986, **13**, 899–902. [PubMed]

76. Silman, A.A.; MacGregor, A.A.; Thomson, W.; Holligan, S.; Carthy, D.; Farhan, A.; Ollier, W.E. Twin concordance rates for rheumatoid arthritis: Results from a nationwide study. *Br. J. Rheumatol.* 1993, **32**, 903–907. [CrossRef] [PubMed]

77. MacGregor, A.A.; Sniedder, H.; Rigby, A.A.; Koskenvuo, M.; Kaprio, J.; Aho, K.; Silman, A.J. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis Rheum.* 2000, **43**, 30–37. [CrossRef]

78. Hemminki, K.; Li, X.; Sundquist, J.; Sundquist, K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. *Arthritis Rheum.* 2009, **60**, 661–668. [CrossRef] [PubMed]

79. Gregersen, P.K.; Silver, J.; Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987, **30**, 1205–1213. [CrossRef] [PubMed]
80. Gonzalez-Gay, M.A.; Garcia-Porrua, C.; Hajeer, A.H. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. *Semin. Arthritis Rheum.* 2002, 31, 355–360. [CrossRef] [PubMed]

81. van Gaalen, F.F.; van Aken, J.; Huizinga, T.T.; Schreuder, G.G.; Breedveld, F.F.; Zanelli, E.; van Venrooij, W.J.; Verweij, C.L.; Toes, R.E.; de Vries, R.R. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. *Arthritis Rheum.* 2004, 50, 2113–2121. [CrossRef] [PubMed]

82. Okada, Y.; Wu, D.; Trynka, G.; Raj, T.; Terao, C.; Ikari, K.; Kochi, Y.; Ohmura, K.; Suzuki, A.; Yoshida, S.; et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* 2014, 506, 376–381. [CrossRef] [PubMed]

83. Yamamoto, K.; Okada, Y.; Suzuki, A.; Kochi, Y. Genetic studies of rheumatoid arthritis. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 2015, 91, 410–422. [CrossRef] [PubMed]

84. Saag, K.G.; Cerhan, J.R.; Kolluri, S.; Ohashi, K.; Hunninghake, G.W.; Schwartz, D.A. Cigarette smoking and rheumatoid arthritis severity. *Ann. Rheum. Dis.* 1997, 56, 463–469. [CrossRef] [PubMed]

85. Hutchinson, D.; Shepstone, L.; Moots, R.; Lear, J.T.; Lynch, M.P. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. *Ann. Rheum. Dis.* 2001, 60, 223–227. [CrossRef] [PubMed]

86. Alspaugh, M.A.; Jensen, F.C.; Rabin, H.; Tan, E.M. Lymphocytes transformed by Epstein—Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. *J. Exp. Med.* 1978, 147, 1018–1027. [CrossRef] [PubMed]

87. Costenbader, K.H.; Karlson, E.W. Epstein–Barr virus and rheumatoid arthritis: Is there a link? *Arthritis Res. Ther.* 2006, 8, 204. [CrossRef] [PubMed]

88. Lundberg, K.; Wegner, N.; Yucel-Lindberg, T.; Venables, P.J. Periodontitis in RA-the citrullinated enolase connection. *Nat. Rev. Rheumatol.* 2010, 6, 727–730. [CrossRef] [PubMed]

89. Rosenstein, E.D.; Greenwald, R.A.; Kushner, L.J.; Weissmann, G. Hypothesis: The humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. *Inflammation* 2004, 28, 311–318. [CrossRef] [PubMed]

90. Cutolo, M.; Accardo, S. Sex hormones, HLA and rheumatoid arthritis. *Clin. Exp. Rheumatol.* 1991, 9, 641–646. [PubMed]

91. Cutolo, M.; Villaggio, B.; Craviotto, C.; Pizzorni, C.; Seriolo, B.; Sulli, A. Sex hormones and rheumatoid arthritis. *Autoimmun. Rev.* 2002, 1, 284–289. [CrossRef]

92. Cantorna, M.T.; Hayes, C.E.; DeLuca, H.F. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. *J. Nutr.* 1998, 128, 68–72. [PubMed]

93. Merlino, L.L.; Curtis, J.; Mikuls, T.T.; Cerhan, J.J.; Criswell, L.L.; Saag, K.K. Iowa Women’s Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women’s Health Study. *Arthritis Rheum.* 2004, 50, 72–77. [CrossRef] [PubMed]

94. Stolt, P.; Kaliberg, H.; Lundberg, I.; Sjogren, B.; Klareskog, L.; Alfredsson, L. EIRA Study Group. Silica exposure is associated with increased risk of developing rheumatoid arthritis: Results from the Swedish EIRA study. *Ann. Rheum. Dis.* 2005, 64, 582–586. [CrossRef] [PubMed]

95. Araki, Y.; Mimura, T. The Mechanisms Underlying chronic inflammation in rheumatoid arthritis from the perspective of the epigenetic landscape. *J. Immunol. Res.* 2016, 2016, 6290682. [CrossRef] [PubMed]

96. Araki, Y.; Mimura, T. The histone modification code in the pathogenesis of autoimmune diseases. *Mediat. Inflamm.* 2017, 2017, 2608605. [CrossRef] [PubMed]

97. Noss, E.H.; Brenner, M.B. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. *Immunol. Rev.* 2008, 223, 252–270. [CrossRef] [PubMed]

98. Filer, A. The fibroblast as a therapeutic target in rheumatoid arthritis. *Curr. Opin. Pharmacol.* 2013, 13, 413–419. [CrossRef] [PubMed]

99. Bartok, B.; Firestein, G.S. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. *Immunol. Rev.* 2010, 233, 233–255. [CrossRef] [PubMed]

100. Frisenda, S.; Perricone, C.; Valesini, G. Cartilage as a target of autoimmunity: A thin layer. *Autoimmun. Rev.* 2013, 12, 591–598. [CrossRef] [PubMed]
101. Yamanaka, H.; Matsuda, Y.; Tanaka, M.; Sendo, W.; Nakajima, H.; Taniguchi, A.; Kamatani, N. Serum matrix metalloproteinase-3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. *Arthritis Rheum.* 2000, 43, 852–858. [CrossRef] [PubMed]

102. Green, M.M.; Gough, A.A.; Devlin, J.; Smith, J.; Astin, P.; Taylor, D.; Emery, P. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. *Rheumatology* 2003, 42, 83–88. [CrossRef] [PubMed]

103. Shinozaki, M.; Inoue, E.; Nakajima, A.; Haru, M.; Tomatsu, T.; Kamatani, N.; Yamanaka, H. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. *Mod. Rheumatol.* 2007, 17, 403–408. [CrossRef] [PubMed]

104. Litinsky, I.; Paran, D.; Levartovsky, D.; Wigler, I.; Kaufman, I.; Yaron, I.; Caspi, D.; Elkayam, O. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. *Cytokine* 2006, 33, 106–110. [CrossRef] [PubMed]

105. Catrina, A.A.; Lampia, J.; Ernestam, S.; af Klint, E.; Klareskog, L.; Ulfgren, A.K. Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. *Rheumatology* 2002, 41, 484–489. [CrossRef] [PubMed]

106. Miller, M.M.; Manning, H.H.; Jain, A.; Troeberg, L.; Dudhia, J.; Essex, D.; Sandison, A.; Seiki, M.; Nanchahal, J.; Nagase, H.; et al. Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. *Arthritis Rheum.* 2009, 60, 686–697. [CrossRef] [PubMed]

107. Sabeh, F.; Fox, D.; Weiss, S.J. Membrane-type I matrix metalloproteinase-dependent regulation of rheumatoid arthritis synovioyte function. *J. Immunol.* 2010, 184, 6396–6406. [CrossRef] [PubMed]

108. Kaneko, K.; Williams, R.O.; Dransfield, D.T.; Nixon, A.E.; Sandison, A.; Itoh, Y. Selective inhibition of membrane type 1 matrix metalloproteinase abrogates progression of experimental inflammatory arthritis: Synergy with tumor necrosis factor blockade. *Arthritis Rheumatol.* 2016, 68, 521–531. [CrossRef] [PubMed]

109. Cox, J.H.; Starr, A.E.; Kappelhoff, R.; Yan, R.; Roberts, C.R.; Overall, C.M. Matrix metalloproteinase-8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression. *Arthritis Rheum.* 2010, 62, 3645–3655. [CrossRef] [PubMed]

110. Itoh, T.; Matsuda, H.; Tanioka, M.; Kuwabara, K.; Itohara, S.; Suzuki, R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. *J. Immunol.* 2002, 169, 2643–2647. [CrossRef] [PubMed]

111. Mudgett, J.J.; Hutchinson, N.N.; Chartrain, N.N.; Forsyth, A.A.; McDonnell, J.; Singer, I.I.; Bayne, E.K.; Flanagan, J.; Kawka, D.; Shen, C.F.; et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. *Arthritis Rheum.* 1998, 41, 110–121. [CrossRef] [PubMed]

112. Brown, P.D. Clinical studies with matrix metalloproteinase inhibitors. *JAMA* 1999, 707, 174–180. [CrossRef] [PubMed]

113. Quan, L.D.; Thiele, G.M.; Tian, J.; Wang, D. The development of novel therapies for rheumatoid arthritis. *Expert Opin. Ther. Pat.* 2008, 18, 723–738. [CrossRef] [PubMed]

114. Wood, N.D.; Aitken, M.; Durston, S.; Harris, S.; McClelland, G.R.; Sharp, S. Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. *Agents Actions Suppl.* 1999, 49, 49–55. [PubMed]

115. Hemnings, F.J.; Farhan, M.; Rowland, J.; Banken, L.; Jain, R. Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. *Rheumatology* 2001, 40, 537–543. [CrossRef] [PubMed]

116. Lewis, E.E.; Bishop, J.; Bottomley, K.K.; Bradshaw, D.; Brewster, M.; Broadhurst, M.J.; Brown, P.A.; Budd, J.M.; Elliott, L.; Greenham, A.K.; et al. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. *Br. J. Pharmacol.* 1997, 121, 540–546. [CrossRef] [PubMed]

117. Brewster, M.; Lewis, E.J.; Wilson, K.L.; Greenham, A.K.; Bottomley, K.M. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. *Arthritis Rheum.* 1998, 41, 1639–1644. [CrossRef] [PubMed]

118. Close, D.R. Matrix metalloproteinase inhibitors in rheumatic diseases. *Ann. Rheum. Dis.* 2001, 60, ii62–ii67. [PubMed]

119. Keystone, E. Treatments no longer in development for rheumatoid arthritis. *Ann. Rheum. Dis.* 2002, 61, ii43–ii45. [CrossRef] [PubMed]
120. Jungel, A.; Ospelt, C.; Lesch, M.; Thiel, M.; Sunyer, T.; Schorr, O.; Michel, B.A.; Gay, R.E.; Kolling, C.; Flory, C.; et al. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. *Ann. Rheum. Dis.* 2010, 69, 898–902. [CrossRef] [PubMed]

121. Kelwick, R.; Desanlis, I.; Wheeler, G.N.; Edwards, D.R. The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. *Genome Biol.* 2015, 16, 113. [CrossRef] [PubMed]

122. Blobel, C.P. Metalloprotease-disintegrins: Links to cell adhesion and cleavage of TNF α and Notch. *Cell* 1997, 90, 589–592. [CrossRef]

123. Moss, M.M.; Jin, S.S.; Milla, M.M.; Bickett, D.D.; Burkhart, W.; Carter, H.L.; Chen, W.J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. *Nature* 1997, 385, 733–736. [CrossRef] [PubMed]

124. Tortorella, M.M.; Burn, T.T.; Pratta, M.M.; Abbaszade, I.; Hollis, J.J.; Liu, R.; Rosenfeld, S.A.; Copeland, R.A.; Decicco, C.P.; Wynn, R.; et al. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins. *Science* 1999, 284, 1664–1666. [CrossRef] [PubMed]

125. Tortorella, M.; Pratta, M.; Liu, R.; Abbaszade, I.; Ross, H.; Burn, T.; Arner, E. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. *J. Biol. Chem.* 2000, 275, 25791–25797. [CrossRef] [PubMed]

126. Araki, Y.; Fann, M.; Wersto, R.; Weng, N.P. Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: Perforin and granzyme B). *J. Immunol.* 2008, 180, 8102–8108. [CrossRef] [PubMed]

127. Araki, Y.; Wang, Z.; Zang, C.; Rosefeld, J.J.; Schones, D.D.; Barski, A.; Cuddapah, S.; Cui, K.; Roh, T.Y.; Peng, W.; Zhang, M.Q.; et al. Combinatorial patterns of histone acetylations and methylations in the human genome. *Nature* 2008, 40, 897–903. [CrossRef] [PubMed]

128. Greer, E.L.; Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. *Nat. Rev. Genet.* 2012, 13, 343–357. [CrossRef] [PubMed]
142. Wei, H.; Mundade, R.; Lange, K.C.; Lu, T. Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle 2014, 13, 32–41. [CrossRef] [PubMed]
143. Wood, A.; Shilatifard, A. Posttranslational modifications of histones by methylation. Adv. Protein Chem. 2004, 67, 201–222. [PubMed]
144. Di Lorenzo, A.; Bedford, M.T. Histone arginine methylation. FEBS Lett. 2011, 585, 2024–2031. [CrossRef] [PubMed]
145. Zhang, Y.; Reinberg, D. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev. 2001, 15, 2343–2360. [CrossRef] [PubMed]
146. Barski, A.; Cuddapah, S.; Cui, K.; Roh, T.T.; Schones, D.D.; Wang, Z.; Wei, G.; Chepelev, I.; Zhao, K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129, 823–837. [CrossRef] [PubMed]
147. Kuo, M.H.; Allis, C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998, 20, 615–626. [CrossRef]
148. Lee, K.K.; Workman, J.L. Histone acetyltransferase complexes: One size doesn’t fit all. Nat. Rev. Mol. Cell Biol. 2007, 8, 284–295. [CrossRef] [PubMed]
149. de Ruijter, A.J.; van Gennip, A.H.; Caron, H.N.; Kemp, S.; van Kuilenburg, A.B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 2003, 370, 737–749. [CrossRef] [PubMed]
150. Yang, X.J.; Gregoire, S. Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol. Cell. Biol. 2005, 25, 2873–2884. [CrossRef] [PubMed]
151. Song, C.; Zhu, Y.; Wu, C.; Kang, J. Histone deacetylase (HDAC) 10 suppresses cervical cancer metastasis through inhibition of matrix metalloproteinase (MMP) 2 and 9 expression. J. Biol. Chem. 2013, 288, 28021–28033. [CrossRef] [PubMed]
152. Mani, S.S.; Kern, C.C.; Kimbrough, D.; Addy, B.; Kasiginesan, H.; Rivers, W.T.; Patel, R.K.; Chou, J.C.; Spinale, F.G.; Mukherjee, R.; et al. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2015, 308, H1391–H1401. [CrossRef] [PubMed]
153. Kowluru, R.A.; Shan, Y.; Mishra, M. Dynamic DNA methylation of matrix metalloproteinase-9 in the development of diabetic retinopathy. Lab. Invest. 2016, 96, 1040–1049. [CrossRef] [PubMed]
154. Lin, H.F.; Hsi, E.; Huang, L.C.; Liao, Y.C.; Juo, S.H.; Lin, R.T. Methylation in the matrix metalloproteinase-2 gene is associated with cerebral ischemic stroke. J. Investig. Med. 2017, 65, 794–799. [CrossRef] [PubMed]
155. Campos, K.; Gomes, C.C.; Farias, L.C.; Silva, R.M.; Letra, A.; Gomez, R.S. DNA methylation of MMP9 is associated with high levels of MMP-9 messenger RNA in periapical inflammatory lesions. J. Endod. 2016, 42, 127–130. [CrossRef] [PubMed]
156. Chang, T.C.; Mendell, J.T. microRNAs in vertebrate physiology and human disease. Annu. Rev. Genom. Hum. Genet. 2007, 8, 215–239. [CrossRef] [PubMed]
157. Ghildiyal, M.; Zamore, P.D. Small silencing RNAs: An expanding universe. Nat. Rev. Genet. 2009, 10, 94–108. [CrossRef] [PubMed]
158. Haussler, J.; Zavolan, M. Identification and consequences of miRNA-target interactions—beyond repression of gene expression. Nat. Rev. Genet. 2014, 15, 599–612. [CrossRef] [PubMed]
159. Jiang, W.; Zhang, Z.; Yang, H.; Lin, Q.; Han, C.; Qin, X. The involvement of miR-29b-3p in arterial calcification by targeting matrix metalloproteinase-2. Biomed Res. Int. 2017, 2017, 6713606. [CrossRef] [PubMed]
160. Chen, P.P.; Tang, C.C.; Lin, L.L.; Tsai, C.C.; Chu, C.C.; Lin, T.H.; Huang, Y.L. Thrombospordin-2 promotes prostate cancer bone metastasis by the up-regulation of matrix metalloproteinase-2 through down-regulating miR-376c expression. J. Hematol. Oncol. 2017, 10, 33. [CrossRef] [PubMed]
161. Xu, Y.Q.; Zhang, Z.H.; Zheng, Y.F.; Feng, S.Q. Dysregulated miR-133a mediates loss of type II collagen by directly targeting matrix metalloproteinase 9 (MMP9) in human intervertebral disc degeneration. Spine (Phila Pa 1976) 2016, 41, E717–E724. [CrossRef] [PubMed]
162. Li, H.R.; Cui, Q.; Dong, Z.Y.; Zhang, J.H.; Li, H.Q.; Zhao, L. Downregulation of miR-27b is involved in loss of type II collagen by directly targeting matrix metalloproteinase 13 (MMP13) in human intervertebral disc degeneration. Spine (Phila Pa 1976) 2016, 41, E116–E123. [CrossRef] [PubMed]
163. Zhang, W.W.; Chen, Y.Y.; Meng, H.H.; Du, J.J.; Luan, G.G.; Wang, H.Q.; Yang, M.W.; Luo, Z.J. Role of miR-155 in the regulation of MMP-16 expression in intervertebral disc degeneration. *J. Orthop. Res.* 2017, in press. [CrossRef] [PubMed]

164. Ni, X.; Xia, T.; Zhao, Y.; Zhou, W.; Wu, N.; Liu, X.; Ding, Q.; Zha, X.; Sha, J.; Wang, S. Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. *Cancer Sci.* 2014, 105, 18–25. [CrossRef] [PubMed]

165. Shilatifard, A. The COMPASS family of histone H3K4 methylases: Mechanisms of regulation in development and disease pathogenesis. *Annu. Rev. Biochem.* 2012, 81, 65–95. [CrossRef] [PubMed]

166. Trenkmann, M.; Brock, M.; Gay, R.R.; Kolling, C.; Speich, R.; Michel, B.A.; Gay, S.; Huber, L.C. Expression and function of EZH2 in synovial fibroblasts: Epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. *Ann. Rheum. Dis.* 2011, 70, 1482–1488. [CrossRef] [PubMed]

167. Karouzakis, E.; Gay, R.E.; Michel, B.A.; Gay, S.; Neidhart, M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. *Arthritis Rheum.* 2009, 60, 3613–3622. [CrossRef] [PubMed]

168. Stanczyk, J.; Pedrioli, D.D.; Brentano, F.; Sanchez-Pernaute, O.; Kolling, C.; Gay, R.E.; Detmar, M.; Gay, S.; Kyburz, D. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. *Arthritis Rheum.* 2008, 58, 1001–1009. [CrossRef] [PubMed]

169. Stanczyk, J.; Ospelt, C.; Karouzakis, E.; Filer, A.; Raza, K.; Kolling, C.; Gay, R.E.; Detmar, M.; Gay, S.; Kyburz, D. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. *Arthritis Rheum.* 2011, 63, 373–381. [CrossRef] [PubMed]

170. Long, L.; Yu, P.; Liu, Y.; Wang, S.; Li, R.; Shi, J.; Zhang, X.; Li, Y.; Sun, X.; Zhou, B.; et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. *Clin. Dev. Immunol.* 2013, 2013, 296139. [CrossRef] [PubMed]

171. Sweeney, S.E.; Hammaker, D.; Boyle, D.L.; Firestein, G.S. Regulation of c-Jun phosphorylation by the IκB kinase-ε complex in fibroblast-like synoviocytes. *J. Immunol.* 2005, 174, 6424–6430. [CrossRef] [PubMed]

172. Philippe, L.; Alsaleh, G.; Suffert, G.; Meyer, A.; Georgel, P.; Sibilia, J.; Wachsmann, D.; Pfeffer, S. TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. *J. Immunol.* 2012, 188, 454–461. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).